Related Experiment Video

Updated: May 11, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Pre-activation of the p53 pathway through Nutlin-3a sensitises sarcomas to drozitumab therapy

Kathleen I Pishas1, Susan J Neuhaus, Mark T Clayer

  • 1Centre for Personalised Cancer Medicine, The University of Adelaide, Adelaide, South Australia, Australia.

Oncology Reports
|May 15, 2013
PubMed

Insights

Drozitumab, a novel antibody targeting death receptor 5 (DR5), shows potential against sarcomas. Combining it with p53-activating agents enhances its cancer-fighting effects by increasing DR5 expression.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Bone and soft-tissue sarcomas remain challenging to treat.
  • Targeting death receptor 5 (DR5) presents a potential therapeutic strategy.
  • The role of the p53 pathway in DR5-mediated apoptosis requires further elucidation.

Purpose of the Study:

  • To evaluate the anti-tumor efficacy of drozitumab, a DR5-targeting antibody, in sarcomas.
  • To investigate the synergistic potential of combining drozitumab with Nutlin-3a, a p53 activator.
  • To determine the role of p53 in regulating DR5 expression and drozitumab sensitivity.

Main Methods:

  • In vitro studies using sarcoma cell lines.
  • Ex vivo analysis of human sarcoma patient samples.
  • Drozitumab monotherapy and combination therapy with Nutlin-3a.
  • p53 knockdown experiments to assess its regulatory role.

Main Results:

  • Drozitumab demonstrated anti-tumor activity in sarcoma models.
  • Combination with Nutlin-3a upregulated DR5 expression and sensitized cells to drozitumab.
  • p53 knockdown significantly reduced DR5 mRNA and abrogated drozitumab-induced apoptosis.
  • Enhanced sensitivity to drozitumab was observed in both cell lines and patient samples.

Conclusions:

  • Drozitumab is a promising therapeutic agent for sarcoma treatment.
  • Activating the p53 pathway enhances sarcoma cell sensitivity to drozitumab.
  • This combination therapy represents a novel strategy to improve DR5 antibody efficacy in sarcomas.

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...